Skip to main content

For adults with moderate to severe hidradenitis suppurativa

Hero banner

TAKE COSENTYX® (secukinumab) EVERY 4 WEEKS

Convenient once-every-4-week dosing

The recommended dose of COSENTYX for adults with moderate to severe hidradenitis suppurativa is 300 mg. To start, your doctor may prescribe 5 weekly loading doses. To continue after that, you only need to take COSENTYX every 4 weeks thereafter.

Use COSENTYX exactly as prescribed by your doctor. 

If your doctor decides that you or a caregiver may give your injections at home, you should receive training on the right way to prepare and inject COSENTYX. Do not try to inject COSENTYX yourself, until you or your caregiver have been shown how by your doctor.

dosing charts

If you continue to have HS symptoms, your dermatologist may prescribe COSENTYX every 2 weeks.

Each 300-mg dose is given as 1 injection of 300 mg or 2 injections of 150 mg under the skin.

The COSENTYX UnoReady® Pen is designed for comfortable use

300-mg UnoReady Pen showing concealed needle, viewing window, pull-off cap, with clear confirmation clicks and no button to press
The COSENTYX UnoReady Pen has a 100% satisfaction rating.
  • The UnoReady Pen is a single, 300-mg injection

  • Design is convenient and easy to use

  • The needle is hidden

  • The cap is not made with natural rubber latex

  • The majority of people experience no pain with the injection§

Download and print the step-by-step Instructions for Use so you can have them handy whenever you need them. For more information about using the UnoReady Pen or the Sensoready® Pen, download and print the Quick Tips Brochure.

Based on a study in which all 37 participants using the UnoReady Pen reported being satisfied or very satisfied with the device at 28 weeks for patients with moderate to severe plaque psoriasis.  
§Based on a study in which 30 of 38 participants using the UnoReady Pen reported no pain with the injection at 12 weeks.

*Limitations apply. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice.